Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Sulindac and Plant Compounds in Preventing Colon Cancer
Terminated
National Cancer Institute (NCI)
N/A
1996-08-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of sulindac may be an effective way to prevent
colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some
types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may
prevent the development of colon cancer.
PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin,
and quercetin in preventing colon cancer.
Sulindac and Plant Compounds in Preventing Colon Cancer
Terminated
University of Medicine and Dentistry of New Jersey
N/A
1996-08-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of sulindac may be an effective way to prevent
colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some
types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may
prevent the development of colon cancer.
PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin,
and quercetin in preventing colon cancer.
Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps
Completed
Chao Family Comprehensive Cancer Center
Phase 2
2000-06-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of eflornithine and sulindac may be an
effective way to prevent the development of colorectal cancer in patients who have had
surgery to remove benign colorectal polyps.
PURPOSE: Randomized, double-blinded, phase II trial to determine the effectiveness of
eflornithine plus sulindac compared to a placebo in preventing colorectal cancer in patients
who have had surgery to remove benign colorectal polyps.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
